

February 2, 2024

The Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai 400 001 Scrip Code: 543427

The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Presentation for Earnings Call with Analysts/Institutional Investors on un- audited Financial Results for the quarter ended December 31, 2023

Pursuant to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to our letter dated January 20, 2024, please find enclosed herewith the presentation for Earnings Call with Analysts/Institutional Investors on un-audited Financial Results for the quarter ended December 31, 2023 scheduled to be held on Monday, February 5, 2024 at 16:00 Hrs.

Kindly take the same on record. The same is being uploaded on the website of the Company.

Thanking You Yours faithfully

For MedPlus Health Services Limited

MANOJ KUMAR Digitally signed by MANOJ SRIVASTAVA

Date: 2024.02.02 17:37:06 +05'30'

Manoj Kumar Srivastava **Company Secretary & Compliance Officer** FCS 7460

Enclosed: a/a

040-6724 6724



THIRD QTR FY2024

ledPlust

10

10

-

HLYN.

HLYN

1 Contest

MEDICOLINS

MEDICOLINS

INVESTOR PRESENTATION

Corporate information Performance update Financial results

Feb 2, 2024



Safe Harbour


This presentation and the accompanying slides (the "Presentation"), which have been prepared by MedPlus Health Services Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the healthcare industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

MedPlus **H**

The MedPlus Story



Q3 FY2024 Highlights (1/2)

₹ 14,415m Revenue

- ₹ 2,512m increase over Q3FY23 21.1% yoy
- ₹ 329m increase over Q2FY24. 2.3% qoq
- 0.7% increase in private label over Q3FY23

144 Store Net Additions

- 164 gross additions
- 89 net additions beyond Tier-One
- 4,233 stores as on 31-Dec-23

₹ 505m Pharmacy Operating EBITDA

- 3.6% Operating EBITDA margin in Pharmacy (increased by 40 bps qoq)
- ₹ 466m Company Operating EBITDA

₹ 3,187m Gross Margin

• 22.1% gross margin (0.5% qoq)

Stores > 12 months

- 12.9% revenue growth over Q3FY23
- 9.6% Store Level EBITDA margin
- 52.5% Store Level Operating ROCE


₹ 412m Operating Cash Flow

- 88.4% OCF/ Operating EBITDA
- ₹ 1,986m closing cash balance




Q3 FY2024 Highlights (2/2)






Pharmacy Retail is Most Attractive Segment of Indian Retail



MedPlus 🖶

Cluster Based Network Enables Profitable Omni-Channel Service



Med Plus 🖶



Scale Allows A Large Private Label Basket: 1000+ SKUs



Poised for Growth


Key Pillars Of Growth

A	Growth in existing clusters and develop new clusters	 MedPlus has an established base of operations in 10 states. Therefore, we will: Further grow in cities where we have market leadership. Metro and Tier - One followed by Tier - Two and beyond Replicate our leadership in markets where we have entered but yet to attain market leadership
---	--	--

в	Leverage our leadership in omni-channel	 MedPlus has built an extensive in-house technology platform. On the back of that, we will: Expand our target addressable market via omni-channel offering Increase retention via omni-channel Operationally extend <2 hour delivery to more locations
---	---	---

с	Expand share of private label: Higher margins and higher share of wallet	 MedPlus has a curated private label range of 1000+ SKUs. From these, we will: Increase private label contribution in pharma products, especially in sub-chronic and chronic ailments Increase private label contribution in FMCG products, including nutrition and wellness
---	--	---

676 Stores Added In Last 12 Months




3. Color index for pie-chart as below:

Metro Tier-One


Tier-Three+

Tier-Two

144 Stores Added In Last Quarter




Young Store Network: 18% Less Than 12 Months Old




11

Profitable Older Stores: 12+ Months




Store Level Revenue Growth¹


Store Level EBITDA Margin




Store Level Operating ROCE^{2,3}



Operating EBITDA, ₹m



Operating EBITDA Margin



3. Annualized by multiplying the quarterly computation by 4

Med Plus 🖶

Revenue Mix: Increasing Share Of Private Label


Revenue Mix: By Product Category Revenue Mix³: By Location of Stores 2.7% 2.9% 2.2% 2.3% Product mix 10% 5.1% 5.7% 5.6% 10% 11% 11% 12% 6.3% 8.6% 7.8% 8.4% Trend of 7.9% 8.1% increasing share 10.7% 23% 11.0% 23% 10.9% 10.9% 23% 23% 11.8% 23% from Private Label continues 11% 12% 12% 13% 13% Location mix 73.6% 72.9% 72.8% 72.4% Maintaining trend 70.9% of growth beyond 56% 56% 54% 53% 52% Metro and Tier-One Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 **Q3FY23** Q4FY23 Q1FY24 **Q2FY24** Q3FY24 ■ Metro ■ Tier-One Tier-Two Tier-Three+ ■ B. Pharma ■ B. Non-Pharma ■ PL. Pharma ■ PL. Others ■ Others

1. Prefix of "B" implies Branded, Prefix of "PL" implies Private Label

2. "Others" includes revenue from franchisee, optical, clinics and labs

3. Only revenue from pharmacy stores

Omni-channel: Profitable With Negligible Acquisition Costs



Income Statement

Snapshot of Income Statement, ₹m

	Q3FY23	Q2FY24	Q3FY24	Q3FY24 vs. Q3FY23 (yoy)	Q3FY24 vs. Q2FY24(qoq)	9m FY23	9m FY24	9m FY24 vs. 9m FY23 (yoy)
Revenue	11,903.1	14,085.9	14,414.7	21.1%	2.3%	33,045.9	41,343.6	25.1%
Gross Margin	2,638.1	3,044.9	3,187.3	20.8%	4.7%	7,168.8	8,966.3	25.1%
Gross Margin	22.2%	21.6%	22.1%			21.7%	21.7%	
Expenses	2,267.6	2,635.0	2,721.3	20.0%	3.3%	6,294.1	7,799.5	23.9%
Operating EBITDA	370.5	409.9	466.0	25.8%	13.7%	874.7	1,166.7	33.4%
Operating EBITDA	3.1%	2.9%	3.2%			2.6%	2.8%	
Rental Expenses	461.1	532.6	535.6	16.1%	0.6%	1,286.6	1,568.3	21.9%
ESOP Expenses	(54.2)	(42.0)	(33.7)	-37.9%	-19.8%	(178.4)	(117.7)	-34.0%
Interest Income	53.5	54.0	47.8	-10.7%	-11.6%	181.3	160.3	-11.5%
EBITDA	830.8	954.6	1,015.7	22.2%	6.4%	2,164.2	2,777.6	28.3%
EBITDA	7.0%	6.8%	7.0%			6.5%	6.7%	
Depreciation & Amortization	(457.9)	(554.7)	(571.1)	24.7%	3.0%	(1,257.6)	(1,650.0)	31.2%
Finance Costs	(210.8)	(235.4)	(245.0)	16.2%	4.1%	(607.6)	(713.1)	17.4%
PBT	162.1	164.4	199.6	23.1%	21.4%	299.0	414.5	38.6%
PAT	133.8	145.4	137.0	2.4%	-5.8%	235.4	320.1	36.0%
PAT	1.1%	1.0%	1.0%			0.7%	0.8%	


Income Statement: Business Segments

Snapshot of Income Statement, ₹m

	Q2FY24				Q3FY24			
	Pharmacy Retail	Diagnostic	Others	Total	Pharmacy Retail	Diagnostic	Others	Total
Revenue	13,884.8	181.5	19.5	14,085.9	14,203.5	196.0	15.2	14,414.7
COGs and Expenses	13,444.6	210.6	20.5	13,675.7	13,698.6	230.2	19.7	13,948.5
Operating EBITDA	440.2	(29.0)	(1.2)	409.9	504.9	(34.1)	(4.8)	466.0
Operating EBITDA	3.2%	-16.0%	-6.3%	2.9%	3.6%	-17.4%	-31.4%	3.2%
Rental Expenses				532.6				535.6
ESOP Expenses				(42.0)				(33.7)
Interest Income				54.0				47.8
EBITDA	954.5						1,015.7	
EBITDA				6.8%				7.0%

Operating EBITDA Deep Dive

Operating EBITDA Bridge: From 12+ Months Stores to Consolidated, ₹m




Balance Sheet


Snapshot of Balance Sheet, ₹m

	Dec-22	Mar-23	Sep-23	Dec-23
Assets				
Non Current Assets				
PPE and CWIP	2,759.8	3,122.4	3,153.1	3,172.0
Intangible assets	476.7	489.9	505.2	509.1
Right-of-use asset	7,511.8	8,022.0	8,427.6	8,542.6
Others	1,648.5	1,525.7	1,674.6	1,691.7
Total Non Current Assets (A)	12,396.8	13,160.0	13,760.5	13,915.4
Current Assets				
Inventories	10,869.1	11,440.9	12,749.2	13,171.9
Cash	3,187.2	2,874.8	2,189.0	1,985.9
Others	799.7	491.5	675.4	711.3
Total Current Assets (B)	14,856.0	14,807.2	15,613.6	15,869.1
Total Assets (A + B)	27,252.8	27,967.2	29,374.1	29,784.5
Equity and Liabilities				
Total Equity	14,592.9	14,911.8	15,227.1	15,458.1
Share application pending allotment	10.0			
Other non current liabilities	7,885.3	8,289.6	8,699.7	8,904.6
Borrowings	2.3	<u>-</u>	<u>-</u>	
Trade payables	2,851.2	2,601.5	2,997.3	3,005.5
Other current liabilities	1,911.1	2,164.4	2,450.1	2,416.3
Total Equity and Liabilities	27,252.8	27,967.2	29,374.1	29,784.5

Capital Productivity




ROCE²: Operating EBIT/ Avg. Capital Employed



- 1. Inventory and Payables (as on end of period) computed on period Revenue
- 2. Annualized by multiplying the quarterly computation by 4

Cash Management



Q3FY24

Appendix

- A. Board and key management
- B. Glossary



A. Board and Key Management

Anish Kumar Saraf

MD at Warburg Pincus

Committed Board



Gangadi Madhukar Reddy 🕳 Founded MedPlus and has led it since inception



Hiroo Mirchandani Senior business leader in healthcare and consumer sectors



Madhavan Ganesan 🛑 Senior business leader. Over 3 decades covering retail and technology

India

- Managing Director & CEO
- Independent Non-Executive Director
- Non-Executive Director
- Whole-Time Director



Dr. Bhaskar Reddy Chief Operating Officer and Whole-Time Director

Murali Sivaraman 🔵

Senior business leader.

Over 3 decades in India

and international markets

Experienced Management Team



Sujit Mahato Chief Financial Officer

Lakshman Kandarpa Chief Retail Officer,



Kandasamy Vairaperumal



Venugopal Siripuram Chief Technology Officer, Optival

Head Supply Chain, Optival

Optival



B. Glossary

Term	Description				
City Categorization (internal)	Metro: Bengaluru, Chennai (and Avadi), Hyderabad, Kolkata (and Howrah), Mumbai (and Thane) Tier One: Ahmednagar, Baramati, Kharagpur, Nagpur, Nashik, Panruti, Pune, Ranaghat, Vijayawada, Visakhapatnam Tier Two: Hundred and Nine cities, including Adilabad, Aurangabad, Coimbatore, Hooghly, Mysuru, Puri				
EBITDA	EBITDA is a non-GAAP financial measure. EBITDA refers to our profit/(loss) for the period, as adjusted to exclude (i) Depreciation and Amortization Expenses, (ii) Finance Costs and (iii) Tax Expense.				
Free Cash Flow (FCF)	Operating Cash Flow minus Capex minus Payment of lease liabilities				
GMV	Gross Merchandising Value (GMV = MRP- GST)				
NWC	Net Working Capital. Inventory <u>plus</u> Receivables <u>minus</u> Trade Payables				
Operating Cash Flow (OCF)	PBT plus non-cash expenditures minus increase in working capital minus taxes paid				
Operating EBITDA	Operating EBITDA is non-GAAP financial measure adjusted for one – off expenses like ESOP				
Store(s)	Our pharmacy stores. Unless specifically mentioned, this does not include our other outlets (e.g optical, clinic, lab, diagnostics, collection center)				
Store age: Year 1, Year 2, Year 2+	For the purpose of age categorization, we determine the age as per the last day of the reporting period. For example a store that has completed 24 months at on the last day of the reporting period, is categorized as Year 2+				
Store Level Operating ROCE	Store Level Operating ROCE is computed by dividing (Store Level Operating EBITDA <u>minus</u> depreciation, assumed as ₹10k p,m./ store for stores aged < 5 years) with Capital Employed. Capital Employed is computed as store level inventory at the end of the period + capex of ₹ 0.6m per store + refundable security deposit.				
Full – Service Center	Full-service center refers to Integrated Diagnostic center with Pathology and Radiology (including MRI and CT)				
Level 2 center	Level 2 center refers to diagnostic center with pathology and Radiology (without CT and MRI)				

MEDPLUS HEALTH SERVICES LIMITED

MILYN

MILYN

MARI

MAR

Tana 1

MEDICOLINS

MEDICOLINS

www.medplusindia.com

COMPANY SECRETARY

Manoj Kumar Srivastava cs@medplusindia.com

INVESTOR RELATIONS Prasad Reddy/ Tanushree Chaurasia ir@medplusindia.com

MEDIA AND PRESS ENQUIRIES marketing@medplusindia.com